Human growth hormone increased the urinary calcium excretion by an average of 64 mg/24 hours in the subject without cancer. This complicates the evaluation of the observed increases in urine calcium resulting from the administration of growth hormone to patients with metastatic cancer.

Human growth hormone did not increase the urinary calcium excretion of six patients with metastatic breast cancer who were in remission. In five patients who did not respond to hypophysectomy, growth hormone increased the excretion of calcium to the same extent as in the control group.

The combined administration of estrogen and growth hormone in two women with estrogen-sensitive mammary cancers did not measurably exacerbate tumor growth.

It was concluded that, for the short periods of administration used in this study, neither human growth hormone nor ovine prolactin measurably increased the activity or rate of growth of metastatic cancer of the breast and prostate.

This content is only available via PDF.